Merck's successful pipeline of new drugs, including LIPFENDRA and mRNA cancer vaccines, has de-risked the company and created a clear pathway for earnings growth that justifies higher valuations.

"The company's leadership responded to this anxiety with a consistent stream of clinical and regulatory successes. The pipeline has produced concrete outcomes, transforming the company from one on the brink of a patent expiration to one that is constructing a dependable pathway for steady earnings growth."

"Even with an over 73% rise in the past twelve months, Merck's 16x multiple underlines that the stock is still undervalued relative to top-tier competitors, suggesting more upside potential if they maintain performance."